Coadministration with Dovato (dolutegravir/lamivudine) has not been studied but is expected to decreased dolutegravir exposure. The US Prescribing Information for Dovato advises to avoid coadministration due to insufficient data to make dosing recommendations. However, the European product label for Dovato recommends an additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato, should be taken. This dose adjustment should be maintained for approximately 2 weeks after stopping St John’s wort as the inducing effect may persist after discontinuation of a strong inducer. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended. No significant interaction is expected with lamivudine. A recent study suggests a low risk of a clinically relevant pharmacokinetic interaction with low-hyperforin formulations (<1 mg/day) of St John’s Wort (hyperforin is the constituent responsible for induction of CYPs and P-gp).